ENTX (Entera Bio) Retained Earnings: $-128.87 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTX Entera Bio Ltd ENTX
23 GF Score
Price $1.99
! 3 Warning Signs
View Full Analysis

What is Entera Bio Retained Earnings?

Entera Bio ENTX -1.00% 23 Retained Earnings is $-128.87 Mil as of Mar. 2026. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Entera Bio's retained earnings for the quarter that ended in Mar. 2026 was $-128.87 Mil.

Entera Bio's quarterly retained earnings declined from Sep. 2025 ($-122.35 Mil) to Dec. 2025 ($-125.37 Mil) and declined from Dec. 2025 ($-125.37 Mil) to Mar. 2026 ($-128.87 Mil).

Entera Bio's annual retained earnings declined from Dec. 2023 ($-104.39 Mil) to Dec. 2024 ($-113.93 Mil) and declined from Dec. 2024 ($-113.93 Mil) to Dec. 2025 ($-125.37 Mil).


Entera Bio  (NAS:ENTX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Entera Bio Retained Earnings Historical Data

* Premium members only.

The historical data trend for Entera Bio's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Retained Earnings Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -82.43 -95.50 -104.39 -113.93 -125.37

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -116.49 -119.15 -122.35 -125.37 -128.87
ENTX
23GF Score
Entera Bio Ltd ENTX
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-128.87 Mil mean?
Entera Bio (ENTX) has a Retained Earnings of $-128.87 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Entera Bio and its competitors.
Is Entera Bio's Retained Earnings too high?
Entera Bio's current Retained Earnings is $-128.87 Mil. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Retained Earnings compare to HRTX and OKYO?
Entera Bio's Retained Earnings of $-128.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Entera Bio and its competitors. Entera Bio's current Retained Earnings is $-128.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current Retained Earnings of $-128.87 Mil. The current Retained Earnings is $-128.87 Mil. Entera Bio's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Entera Bio (ENTX), the current Retained Earnings is $-128.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score

Get the complete analysis for ENTX

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price